PALLIATIVE RADIOTHERAPY IN PLASMA-CELL MYELOMA

被引:33
作者
ADAMIETZ, IA
SCHOBER, C
SCHULTE, RWM
PEEST, D
RENNER, K
机构
[1] MED SCH HANNOVER, DEPT RADIOTHERAPY & SPECIAL ONCOL, W-3000 HANNOVER, GERMANY
[2] MED SCH HANNOVER, DEPT IMMUNOL & TRANSFUS MED, W-3000 HANNOVER, GERMANY
关键词
MULTIPLE MYELOMA; BONE DESTRUCTION; PAIN TREATMENT; RADIOTHERAPY; PALLIATION;
D O I
10.1016/0167-8140(91)90144-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pain symptoms caused by bone lesions of multiple myeloma can be relieved by a local irradiation treatment. To estimate the influence of systemic treatment on the palliative effect of local radiotherapy the records of 70 myeloma patients treated with chemotherapy combined with or followed by local irradiation were reviewed. The local response rate, defined as complete pain relief at the irradiated site, was 80% in patients receiving irradiation during chemotherapy (melphalan and prednisone) and this palliative effect endured 31.8 +/- 3.6 months. If irradiation was started in the period without systemic treatment the local response rate was 39.6% and lasted 24.8 +/- 17.9 months. In sites treated with more than one radiotherapy course 94% response rate after the first treatment, 56% after the second treatment and no response after the third course was achieved. The duration of local pain control was positively related to the applied radiation dose. It is concluded that irradiation during concomitant chemotherapy is superior to radiotherapy performed in a period without systemic treatment. Local long-term palliation can only be achieved by a sufficient high radiation dose.
引用
收藏
页码:111 / 116
页数:6
相关论文
共 28 条
[1]  
ALEXANIAN R, 1980, BLOOD, V56, P521
[2]   INTERNATIONAL VARIATIONS AND TEMPORAL TRENDS IN MORTALITY FROM MULTIPLE-MYELOMA [J].
CUZICK, J ;
VELEZ, R ;
DOLL, R .
INTERNATIONAL JOURNAL OF CANCER, 1983, 32 (01) :13-19
[3]   CANCER INCIDENCE AND MORTALITY TRENDS IN UNITED-STATES - 1935-74 [J].
DEVESA, SS ;
SILVERMAN, DT .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1978, 60 (03) :545-571
[4]  
DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO
[5]  
2-U
[6]  
FARHANGI M, 1973, SEMIN HEMATOL, V10, P149
[7]   PRIMARY BIOASSAY OF HUMAN MYELOMA STEM-CELLS [J].
HAMBURGER, A ;
SALMON, SE .
JOURNAL OF CLINICAL INVESTIGATION, 1977, 60 (04) :846-854
[8]  
Hofmann VE, 1985, INTERNISTISCHE KREBS, P347
[9]   STUDIES ON THE CLONAL ORIGIN OF MULTIPLE-MYELOMA - USE OF INDIVIDUALLY SPECIFIC (IDIOTYPE) ANTIBODIES TO TRACE THE ONCOGENIC EVENT TO ITS EARLIEST POINT OF EXPRESSION IN B-CELL DIFFERENTIATION [J].
KUBAGAWA, H ;
VOGLER, LB ;
CAPRA, JD ;
CONRAD, ME ;
LAWTON, AR ;
COOPER, MD .
JOURNAL OF EXPERIMENTAL MEDICINE, 1979, 150 (04) :792-807
[10]  
LUDWIG H, 1982, J NATL CANCER I, V68, P729